Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention

Human respiratory syncytial virus (hRSV) is the most important viral agent of pediatric respiratory infections worldwide. The only specific treatment available today is a humanized monoclonal antibody (Palivizumab) directed against the F glycoprotein, administered prophylactically to children at ver...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Magro, Margarita, Mas, Vicente, Chappell, Keith, Vázquez, Mónica, Cano, Olga, Luque, Daniel, Terrón, María C., Melero, José A., Palomo, Concepción
פורמט: Artigo
שפה:Inglês
יצא לאור: National Academy of Sciences 2012
נושאים:
Biological Sciences
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3286924/
https://ncbi.nlm.nih.gov/pubmed/22323598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1115941109
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים